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Context: The activating p.Glu17Lys mutation in AKT2, a kinase mediating many of insulin’s met-
abolic actions, causes hypoinsulinemic hypoglycemia and left-sided hemihypertrophy. The wider
metabolic profile and longer-term natural history of the condition has not yet been reported.
Objective: To characterize the metabolic and cellular consequences of the AKT2 p.Glu17Lys mu-
tation in two previously reported males at the age of 17 years.
Design and Intervention: Body composition analysis using dual-energy X-ray absorptiometry, overnight
profiling of plasma glucose, insulin, and fatty acids, oral glucose tolerance testing, andmagnetic resonance
spectroscopy to determine hepatic triglyceride content was undertaken. Hepatic de novo lipogenesis was
quantifiedusingdeuteriumincorporation intopalmitate.Signaling indermal fibroblastswas studiedexvivo.
Results: Both patients had 37% adiposity. One developed hypoglycemia after 2 hours of overnight
fasting with concomitant suppression of plasma fatty acids and ketones, whereas the other
maintained euglycemia with an increase in free fatty acids. Blood glucose excursions after oral
glucose were normal in both patients, albeit with low plasma insulin concentrations. In both pa-
tients, plasma triglyceride concentration, hepatic triglyceride content, and fasting hepatic de novo
lipogenesis were normal. Dermal fibroblasts of one proband showed low-level constitutive
phosphorylation of AKT and some downstream substrates, but no increased cell proliferation rate.
Conclusions: The p.Glu17Lys mutation of AKT2 confers low-level constitutive activity upon the
kinase and produces hypoglycemia with suppressed fatty acid release from adipose tissue, but not
fatty liver, hypertriglyceridemia, or elevated hepatic de novo lipogenesis. Hypoglycemia may
spontaneously remit. (J Clin Endocrinol Metab 102: 2914–2921, 2017)
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In 2004, a single infant was described with a uniquesyndrome encompassing severe, persistent hypoketotic
hypoglycemia despite replete, mobilizable hepatic glycogen
stores andmarked left-sidedhemihyperplasia (1).Although
the biochemical profile mimicked that of hyperinsulinism,
no detectable insulin nor insulin-like substances were de-
tectable at the time of hypoglycemia, and glucose infusion
rates required to maintain euglycemia were much lower
than are required in bona fide hyperinsulism. In 2011, we
identified the de novo p.Glu17Lysmutation inAKT2as the
cause of this syndrome in the initial proband as well as in
two further patients with the same metabolic disorder (2).
AKT2 is a serine/threonine kinase that plays a critical role
in transducing insulin stimulation intometabolic responses in
target tissues, including liver, adipose tissue, and skeletal
muscle. Its activation is normally tightly coupled to stimu-
lation of the insulin receptor by a requirement for
phosphatidylinositol-3,4,5-trisphosphate (PIP3) for its re-
cruitment to the plasma membrane. The p.Glu17Lys muta-
tion relaxes this requirement, permitting binding to the more
abundant membrane phospholipid phosphatidylinositol-4,5-
bisphosphate (PIP2), partially uncoupling AKT2 activation
from insulin stimulation (3, 4).
Since elucidation of the genetic cause of the syndrome,
two further individuals with the same mutation, and
with a similar biochemical profile, have been described
(5, 6), with one report placing emphasis on dysmorphic
features of the syndrome not previously noted (6). More-
over, studies using genome editing in stem cell–derived
adipocytes and hepatocytes have corroborated the basal
activation of the p.Glu17Lys mutation in AKT2 and have
demonstrated activation of critical downstream responses
in target cells, including glucose uptake in adipocytes and
nuclear exclusion of the gluconeogenic transcription factor
FOXO1 in hepatocyte-like cells (7).
Nevertheless, despite this body of evidence linking
AKT2 p.Glu17Lys to hypoketotic hypoglycemia, key ques-
tions remain about the pathogenesis and natural history
of the syndrome. Most critically from a clinical point of
view, it is not yet known whether the tendency to hy-
poglycemia varies during puberty or when linear growth
is completed, whereas from a physiological point of
view, the relative contribution of AKT2 activation in liver
and adipose tissue to hypoglycemia remains to be fully
established. It is also not known whether genetic AKT2
activation in humans leads to accumulation of liver fat or
metabolic dyslipidemia, which is an important question,
as murine studies have strongly implicated AKT2 in the
pathogenesis of fatty liver and related diseases associated
with insulin resistance and hyperinsulinemia (8).
The aim of this study was to assess in more detail the
metabolic phenotype in two of the patients previously
reported, both male and, at the time of study, both
17 years old. Moreover, using dermal fibroblasts isolated
from one patient, we aimed to characterize further the
cellular phenotype associated with AKT2 p.Glu17Lys.
Patients and Methods
All physiological studies were approved by the National Health
Service Research Ethics Committee of the United Kingdom. All
participants provided written informed consent, and all studies
were conducted in accordance with the principles of the Dec-
laration of Helsinki. Patients reserved the right to withdraw
consent at any time.
In vivo studies
Body composition was assessed using Lunar Prodigy dual-
energy X-ray absorptiometry (GE Lunar). Hepatic triglyceride
was assessed using proton magnetic resonance spectroscopy
on a Siemens 3T Verio scanner using methods previously de-
scribed (9) and quantified as the ratio of methylene to combined
methylene and water signals corrected for spin-spin relaxation.
Adipose distribution was determined by magnetic resonance
imaging using T1-weighted turbo spin echo, water-suppressed,
transaxial images, also generated by a Siemens 3TVerio scanner
and pseudocolored for visualization using MATLAB software
(The MathWorks, Inc., Natick, MA). The fractional de novo
synthetic rate of fatty acids was determined by assessing the
incorporation of deuterium into plasma triglyceride after the
administration of deuterium-labeledwater. After a balancedmeal
of standard macronutrient composition at 7 PM, deuterium-
labeled water (3 mL/kg body water, 99.8%; Cambridge Iso-
topes) was administered in two doses of equal size (8 PM, 10 PM).
Blood was collected before and 12 hours after the first loading
dose of deuterium. Deuterium enrichment of plasma palmitate
was determined by gas chromatography/mass spectrometry
(5973N system; Agilent, Santa Clara, CA) and compared with
that of water, determined by isotope ratio mass spectrometry
using a SIRA10 instrument (VG Isotopes Ltd). A reference range
was determined from nine healthy volunteers (9, 10).
For overnight metabolic profiling, participants were admitted
to a clinical research facility and fasted from 10 PM. Samples were
taken hourly for biochemical analysis overnight, or in the event of
symptomatic hypoglycemia. In one participant, hypoglycemic
symptoms developed after 2 hours of fasting, with a blood glucose
of 48 mg/dL, and 200 mL of oral LucozadeTM was given con-
taining 34 g glucose. Seventy-five-gram oral glucose tolerance
testing was undertaken in both study subjects at 8 AM following
the overnight fast, with blood sampling at the times indicated.
Biochemical assays
For measurement of insulin, leptin, and adiponectin, venous
blood was drawn in the fasting state and plasma was imme-
diately extracted and stored at –20°C. Proteins were assayed
using two-step, time-resolved AutoDELFIA immunoassays, in
accordance to the previously described protocols (9, 11, 12).
Normative adiponectin, leptin, and oral glucose tolerance
testing data were derived from a white population from the
Medical Research Council Ely Study cohort, representative of
an ethnically homogeneous white population in this area of
eastern England (11, 13). Reference data for lipid parameters
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were derived from 42 healthy volunteers [women: n = 23, mean
age, 36 years (range, 23 to 62), mean body mass index (BMI),
23.5 kg/m2 (range, 19.1 to 32.7); men: n = 19, mean age, 44
years (range, 22 to 62), mean BMI, 25.5 kg/m2 (range, 18.4 to
31.7)] (9). All other biochemical analyses were undertaken in an
accredited clinical diagnostic laboratory in Addenbrooke’s
Hospital, Cambridge, United Kingdom.
Cellular signaling studies
Human primary dermal fibroblasts from healthy controls
and patient 1 were obtained and cultured using standard
procedures (1). Cell lines were confirmed prior to study by
genotyping of AKT2. Cells were grown to 90%confluence prior
to serum starvation. Serum-free culture medium consisted of
high-glucose Dulbecco’s modified Eagle medium supplemented
with 100 U/L penicillin-streptomycin, 100 mg/mL L-glutamine,
and 0.5% bovine serum albumin. Cells were washed with warm
phosphate-buffered saline and serum starved for 18 to 24 hours
before stimulation. After 18 to 24 hours, serum-free medium was
removed and replaced with serum-free medium containing the
appropriate concentration of insulin (Actrapid; NovoNordisk,
Crawley, United Kingdom), IGF-1 (Abcam, Cambridge, United
Kingdom), or EGF (Sigma-Aldrich, Gillingham, United Kingdom)
for 5 or 10minutes. Cells were then washed with cold phosphate-
buffered saline, snap frozen in liquid nitrogen, and thawed and
scraped in modified radioimmunoprecipitation assay buffer
(substitution of 1% [volume-to-volume ratio] Triton-X 100 in-
stead of sodium dodecyl sulfate) containing Complete Mini
Protease Inhibitor Cocktail (Roche, Burgess Hill, United King-
dom). Protein concentrations were determined with the Bradford
protein assay (Bio-Rad).
Phosphorylation of AKT in cell lysates was assessed using
InstantOneELISAKits (eBioscience, Inc., SanDiego,CA), according
to the manufacturer’s guidelines. The PathScan® Akt Signaling
Antibody Array Kit (Chemiluminescent Readout; Cell Signaling
Technology,Danvers,MA)wasused for simultaneous assessment of
16 phosphorylated proteins within the AKT signaling pathway. All
reagents and the experimental protocol were as provided by the
manufacturer. An image of the slide was captured with a Bio-Rad
ChemiDocMPDigital Imager and analyzed using AlphaView array
analysis software (ProteinSimple, Santa Clara, CA).
For immunoblotting studies, sodium dodecyl sulfate–
polyacrylamide gel electrophoresis was undertaken followed by
transfer to a polyvinylidene difluoride membrane using the iBlot
dry blotting system (Thermo Fisher Scientific, Cramlington,
United Kingdom) and immunoblotting with the appropriate
primary antibodies. Secondary antibodies were either horse-
radish peroxidase linked, in which case, proteins were visual-
ized using enhanced chemoluminescence (GEHealth Care, Little
Chalfont, United Kingdom; Millipore, Billerica, MA), or
IRDye® fluorophore linked, in which case an Odyssey IR
Imaging System (LI-COR Bioscience, Lincoln, NE) was used.
Western blot band intensity was quantified by densitometry and
analyzed using ImageJ software, with intensity of bands of
interest normalized to the intensity of the corresponding loading
control (calnexin, unless indicated otherwise). Primary anti-
bodies used are indicated in the Supplemental Methods.
Statistical analysis
Statistical significance of differences in protein phosphory-
lation was analyzed using the two-tailed, unpaired Student
t test. Differences in cell proliferation rates were assessed by
fitting linear regression lines and then testing for gradient
equality. Significance is shown on all graphs: * denotes P ,
0.05, ** denotes P , 0.01, *** denotes P , 0.001, and
nonsignificant indicates P . 0.05. All bars represent mean 6
standard error of the mean, unless otherwise indicated. All
analyses were performed in GraphPad Prism 5.0 (GraphPad
Software Inc., San Diego, CA).
Results
Physiological study of two affected probands
At the age of 17 years old, two male patients [desig-
nated patient 1 (P1) and patient 2 (P2)] whose early
clinical courses were previously described (2) were
reassessed. Both participants and their families remained
very anxious about hypoglycemia; however, the severity
of this had lessened since early life. P1 still had a per-
cutaneous feeding tube in situ and was receiving over-
night feeding; however, he waswell and active and able to
engage in sport. Although the feeding tube had been
removed in P2 at the age of 11 years, he was only able to
maintain euglycemia using three hourly feeds as well as
an additional bedtime feed with modified maize starch.
He reported significant weakness and easy fatiguability
on exertion.
On examination, both P1 and P2 had generalized
obesity. Cross-sectional imaging demonstrated particularly
marked expansion of subcutaneous adipose tissue, with
visceral fat accounting for only 10.6% and 6.3% of fat in
P1 and P2, respectively (Fig. 1). Corresponding values in 12
healthy male volunteers [mean age, 15.7 years (range, 14.6
to 16.9); mean BMI, 20.2 (range, 16.5 to 23.5); total %
adiposity, 15.0 (range, 7.0 to 30.8)] were 11.0% to 45.8%
(mean, 24.2%). Both patients were also noted to have mild
bilateral ptosis with proptosis, in keeping with the dys-
morphic features described in two previous patients with
the AKT2 p.Glu17Lys mutation (5, 6). Previously noted
left-sided hemihyperplasia remained striking in P1, af-
fecting subcutaneous adipose tissue in particular, but was
only subtle and limited to the face in P2. Body composition
analysis showed both P1 and P2, coincidentally, to have an
identical body adipose content of 37%.
To evaluate fasting tolerance, P1 and P2 underwent an
overnight fast with hourly blood sampling. P1 remained
euglycemic, with a physiologically appropriate increase in
free fatty acids overnight, but with notably low plasma
insulin concentration throughout the night [Fig. 2(a)]. P2,
in contrast, developed symptomatic hypoglycemia after
3 hours of fasting, with suppression of both plasma insulin
and free fatty acids, requiring rescue with a bolus of oral
glucose solution containing 34 g glucose, following which
no further intervention was required [Fig. 2(b)]. Plasma
free fatty acids remained low throughout the night.
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Overnight fasts were immediately followed by oral
glucose tolerance testing to assess the response to a
glucose challenge. In P1, fasting glucose values were
within the normal reference range, whereas P2 was hy-
poglycemic at termination of the overnight fast. After the
glucose challenge, however, glucose levels in both P1 and
P2 exceeded the 50th percentile within 60 minutes, al-
though concomitant insulin excursion tracked below the
50th percentile and 5th percentile in P1 and P2, re-
spectively, with reference to a large population-based
control data set (Fig. 3).
Fasting plasma triglyceride concentrations were nor-
mal for both P1 and P2; however, in both participants,
fasting plasma very low-density lipoprotein (VLDL)
cholesterol and high-density lipoprotein (HDL) choles-
terol concentrations were low. Proton magnetic reso-
nance spectroscopy revealed normal hepatic triglyceride
content, with an intrahepatic lipid-to-water ratio of 0.7%
and 0.1% in P1 and P2, respectively (reference range
from healthy controls ,5.5%). Moreover, there was no
difference in the rate of fasting de novo lipogenesis when
compared with healthy controls (Table 1). Serum leptin
levels were increased in both participants, consistent with
their elevated adiposity, whereas serum adiponectin
concentrations were at or above the top of a reference
range derived from BMI- and sex-matched controls.
Limited evaluation of both parents of P1 was also
undertaken. Both were obese, and the father of P1 had
marked flexural acanthosis nigricans. Biochemical anal-
ysis also revealed the father to have fasting hyper-
insulinemia with normal fasting glucose and suppressed
HDL cholesterol, although other analytes fell within the
reference range. The mother of P1 was also obese, and
insulin and C-peptide were at the upper limit of the
reference range, with normal fasting glucose. The lipid
profile was normal (Supplemental Table 1).
Primary fibroblast signaling studies
Previous studies established a low level of basal
hyperphosphorylation of AKT in primary fibroblasts
from P1. This finding was extended in the same dermal
fibroblasts compared with dermal fibroblasts obtained
from four healthy volunteers. Low-level basal phos-
phorylation of AKTwas confirmed, though, surprisingly,
peak phosphorylation of AKT after stimulation of cells
with insulin or IGF-1 was blunted in P1 cells compared
with controls (Fig. 4). Using a commercially available
immunochip to assay other components of the PI3K/
signaling pathway confirmed patchy activation of path-
ways downstream from AKT, with PRAS40 phosphor-
ylation particularly robust (Supplemental Fig. 1). No
difference in cell proliferation rate between P1 and
control dermal fibroblasts could be discerned, however,
either in serum-replete or serum-starved conditions
(Supplemental Fig. 2).
Additional analyses focused on expression of com-
ponents of the INSR/IGF-1R and EGF signaling pathway,
as several of those are subject to negative feedback after
activation of PI3K/AKT signaling. In P1 cells relative to
healthy controls, there was a decrease in IGF1R, EGFR,
and IRS2 protein levels; however, there were no changes
in IRS1, INSR, p85a, or p110a protein levels, the last two
proteins together comprising a key isoform of type 1A
PI3K that lies upstream in the signaling pathway from
AKT (Supplemental Fig. 2). These findings illustrate the
remodeling of RTK/PI3K/AKT signaling that occurs in
response to tonic low-level activation of AKT2 even in
noncanonically insulin-responsive cells.
Discussion
Aninsulinemic hypoglycemia due to genetic activation of
AKT2 is a rare entity, described to date in only five
patients. Nevertheless, the severity and persistence of the
hypoglycemia dominates the lives of affected children and
their families, who have a pressing need to understand the
Figure 1. Quantification of visceral and subcutaneous adipose
tissue. Representative abdominal fat distribution determined by
magnetic resonance imaging at the L4 vertebral level is shown with
pseudocolored adipose depots for P1, P2, and two healthy sex- and
age-matched controls (C1, C2). Visceral adipose tissue (VAT) is
indicated in yellow, and subcutaneous adipose tissue (SCAT) is
indicated in red.
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natural history of the condition. Moreover, the critical
importance of AKT2 not only in mediating key actions of
insulin in health, but also potentially in driving compo-
nents of the metabolic syndrome such as fatty liver and
dyslipidemia in the face of insulin resistance, lends con-
siderable interest to the wider metabolic observations to
be made in this rare human “experiment of nature.”
Our first significant clinical observation is that one
patient at the age of 17 years old is able to sustain a
normal blood glucose overnight, with a normal increase
in plasma free fatty acids during the night. The second
patient, of the same sex, age, and body composition, in
contrast, has a fasting tolerance of only 2 to 3 hours and
shows suppressed free fatty acid levels throughout the
night. At present, it is not clear whether the propensity to
hypoglycemia of P2will also lessen in due course, nor what
the mechanism underlying diminution of the metabolic
disturbance in P1 is. It is notable that the father of P1 shows
evidence of obesity-related insulin resistance. No similar
parental studies were possible for P2; however, this finding
raises the possibility that, in P1, progressive obesity has led
to a state of insulin resistance determined by inherited,
presumably oligogenic factors and that this is exerted at or
beyond the level of AKT2 in liver and adipose tissue, ef-
fectively attenuating the basal AKT activation that was
driving hypoglycemia and free fatty acid suppression.
One proband reporting previously with the loss-of-
function p.Arg274His mutation in AKT2 showed fem-
orogluteal lipodystrophy (14), whereas both patients
whomwe describe at 17 years old were obese. Moreover,
in murine studies, Akt2 has been suggested to play a
critical role in the expansion of visceral adipose tissue on
exposure of mice to a high-fat diet, and the previous
report of obesity in patients with the AKT2 p.Glu17Lys
mutation has been suggested to support an important cell
autonomous role of AKT2 in adipocyte development
(15). However, evidence that Akt2 activation is necessary
for adipose tissue expansion does not also establish that it is
Figure 2. Overnight profiling of plasma glucose, insulin, and free fatty acid concentrations. Plasma concentrations of glucose, insulin, and free
fatty acids are shown during fasting from 11 PM for (a) P1 and for (b) P2. Midnight is represented by 0 hours. Samples taken during spontaneous
hypoglycemia in P2 are indicated with red icons, whereas administration of an oral “rescue” bolus of 34 g glucose solution is indicated by red
arrows. NEFA, nonesterified fatty acids.
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sufficient, and amajor confounder in the present patients is
chronic caloric excess, engendered by the need to avoid
prolonged fasting and exacerbated by a desire by both
physicians and patients or their families to err on the side of
caution with supplemental feeding. It is notable that adi-
pose expansion in the patients we describe was largely in
subcutaneous depots, rather than being predominantly
visceral, asmight be expected if AKT2 played a preferential
role in mediating expansion of visceral adipose tissue.
Several lines of evidence suggest that hyperinsulinemia
contributes significantly to the fatty liver and dyslipidemia
seen in common insulin-resistant states. Both patients
studied here had normal liver triglyceride content, normal or
low plasma triglyceride concentrations, and normal rates of
fasting de novo lipogenesis despite low-level constitutive
activation of AKT2 and obesity. Conversely, previously
described patients with a loss-of-functionmutation inAKT2
had insulin resistance, with severe fatty liver and dyslipi-
demia, quite unlike patients with severe insulin resistance
due either to mutations in the insulin receptor (9), who
exhibit normal hepatic lipid content, normal rates of fasting
de novo lipogenesis, and a normal plasma lipid profile de-
spite severe insulin resistance, or to mutations in PIK3R1,
encoding a regulatory subunit of PI3K, who also show a
normal lipid profile despite severe insulin resistance (16).
One interpretation of these observations is that AKT2
is not required for hepatic de novo lipogenesis in humans.
Instead, de novo lipogenesis might be dependent on a
branch of the insulin signaling pathway that is down-
stream of the insulin receptor and PI3K, but upstream
from AKT2. In support of this view are two murine
studies that suggest that PKC, and not AKT, contributes
to the increase in Srebp-1c expression (17, 18). Contrary
to these reports, several other groups suggest that
mTORC1 and AKT2 are positive regulators of de novo
lipogenesis (8, 19, 20). Caution should be exercised,
however, in interpreting these human findings solely in
Figure 3. Oral glucose tolerance testing. Plasma glucose and insulin concentrations after a 75-g oral glucose load are shown for (a and b) P1
and (c and d) P2. Testing was undertaken following the overnight fast illustrated in Fig. 2. Sex-matched control data from a large European white
control population from eastern England are shown as 5th, 50th, and 95th percentiles.
Table 1. Biochemical Profile of Patients 1 and 2
With the AKT2 p.Glu17Lys Mutation at 17 Years Old
P1 P2 Reference Range
Age 17 17 —
BMI (kg/m2) 28.6 22 ,25
Glucose (mg/dL) 81 54 ,110
Insulin (mIU/mL) 2.7 ,0.3 0–8.6
C-peptide (ng/mL) 0.7 0.05 0.5–2.7
Leptin (ng/mL) 45.8 113 1.5–13a
Adiponectin (mg/L) 10.1 14.9 P1: 2.4–10.6a
P2: 2.6–12.6a
NEFA (mEq/L) 0.43 0.3 0.2–0.9
Cholesterol, total (mg/dL) 131 112 205–228
HDL cholesterol (mg/dL) 31 41 53–66
LDL cholesterol (mg/dL) 89 66 ,116
VLDL Tg (mmol/L) 27.4 18.6 40–61
Triglyceride (mg/dL) 60 42 102–144
Hepatic triglyceride (%) 0.7 0.1 ,5.5%
Hepatic DNL (%) 1.9 1.8 ,2.5%
Blood was drawn after an overnight fast interrupted by a single bolus of
oral glucose in P2, as described in text.
Abbreviations: DNL, de novo lipogenesis; LDL, low-density lipoprotein;
NEFA, nonesterified fatty acids; Tg, triglyceride.
aBMI- and sex-adjusted reference values.
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terms of the role of AKT2 in the liver. AKT2 is also
expressed in adipose tissue and skeletal muscle, and it is
highly plausible that effects of genetically activated AKT2
in adipose tissue are masking any propensity toward
accumulation of liver fat. Indeed, the clear suppression of
normal overnight increases in fatty acids in one of the
patients studied is most easily explicable by pathological
suppression of lipolysis in adipocytes due to tonic AKT2
action. This would have the effect of reducing one major
source of liver triglyceride, while simultaneously de-
priving the liver of substrate for b oxidation and energy
generation, which has been shown to be important for
gluconeogenesis in murine studies (21). Reduction in free
fatty acid delivery to the liver may explain the low VLDL
cholesterol levels recorded in the patients described.
The cellular signaling studieswe describe illustrate that
the p.Glu17Lys mutation does not confer full activation
of AKT2, but rather a low level of inappropriate basal
activation. Indeed, in the single patient cell line studied,
peak phosphorylation in response to a panel of growth
factors was blunted, likely due to extensive feedback
degradation or suppression of expression of proximal
signaling molecules, including receptors and insulin re-
ceptor substrates. It is not clear, however, whether this
cellular phenomenon has any in vivo correlate. The level of
AKT activation seen appears sufficient to activate some but
not all downstream phosphorylation events. This observa-
tion is in agreementwith cellular evidence thatAKTserves to
amplify and transmit input signals into outputs in a non-
linear manner (22) with different clusters of AKT substrates
identifiable based on their capacity to be phosphorylated by
the different concentrations of insulin (23). This may also
explain why much less glucose is required to maintain
euglycemia in infants with AKT2 p.Glu17Lys, in which the
metabolic defectmay be failure to derepress gluconeogenesis
during fasting, than in those with hyperinsulinism, in whom
there is also inappropriate disposal of glucose into skeletal
muscle and adipose tissue mediated by GLUT4.
Our findings suggest that hypoglycemia driven by the
AKT2 p.Glu17Lys mutant may not be lifelong and may
remit under some circumstances, although whether de-
velopmental, genetic, or environmental modifying factors
are most critical in this remains to be determined. More
generally, we provide evidence for complexity in both the
systemic and cellular consequences of low-grade, constant
AKT2 activation. Detailed study of similar-graded per-
turbations of Akt2 in different mouse tissues is likely to be
required to tease out the interrelationships between Akt2
activation and the phenotype we observe in humans.
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